Marketing-authorisation holder · Canada
Bristol-Myers Squibb Canada
182 medicines in 1 country, as authorisation holder.
Loading your page…
Loading your page…
Marketing-authorisation holder · Canada
182 medicines in 1 country, as authorisation holder.
One free account for the Prognia apps: Ward to study, Osler for clinical answers with their sources, and the network to find your colleagues.
Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.
Every medicine in the registers under its name, current ones first.
1–25 of 182
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| ABRAXANE FOR INJECTABLE SUSPENSION100 mg / vial · Powder For Suspension | Paclitaxel | Canada | Marketed | 2006 |
| BARACLUDE0.5 mg · Tablet | Entecavir | Canada | Marketed | 2006 |
| BREYANZI120000000 cells · Suspension | Lisocabtagene maraleucel | Canada | Marketed | 2024 |
| CAMZYOS10 mg · Capsule | Mavacamten | Canada | Marketed | 2023 |
| CAMZYOS15 mg · Capsule | Mavacamten | Canada | Marketed | 2023 |
| CAMZYOS5 mg · Capsule | Mavacamten | Canada | Marketed | 2023 |
| CAMZYOS2.5 mg · Capsule | Mavacamten | Canada | Marketed | 2023 |
| ELIQUIS5 mg · Tablet | Apixaban | Canada | Marketed | 2012 |
| ELIQUIS2.5 mg · Tablet | Apixaban | Canada | Marketed | 2012 |
| INREBIC100 mg · Capsule | Fedratinib | Canada | Marketed | 2021 |
| ISTODAX10 mg / vial · Kit, Powder For Solution | Romidepsin | Canada | Marketed | 2014 |
| KENALOG-10 INJECTION10 mg / ml · Suspension | Triamcinolone | Canada | Marketed | 1966 |
| KENALOG-40 INJECTION40 mg / ml · Suspension | Triamcinolone | Canada | Marketed | 1973 |
| ONUREG200 mg · Tablet | Azacitidine | Canada | Marketed | 2021 |
| ONUREG300 mg · Tablet | Azacitidine | Canada | Marketed | 2021 |
| OPDIVO10 mg / ml · Solution | Nivolumab | Canada | Marketed | 2015 |
| OPDIVO10 mg / ml · Solution | Nivolumab | Canada | Marketed | 2015 |
| OPDIVO SC120 mg / ml · Solution | Nivolumab | Canada | Marketed | 2025 |
| OPDIVO SC120 mg / ml · Solution | Nivolumab | Canada | Authorised | |
| OPDUALAG240 mg / 20 ml + 80 mg / 20 ml · Solution | Nivolumab, Relatlimab | Canada | Marketed | 2024 |
| ORENCIA250 mg / vial · Powder For Solution | Abatacept | Canada | Marketed | 2006 |
| ORENCIA125 mg / ml · Solution | Abatacept | Canada | Marketed | 2013 |
| POMALYST2 mg · Capsule | Pomalidomide | Canada | Marketed | 2014 |
| POMALYST1 mg · Capsule | Pomalidomide | Canada | Marketed | 2014 |
| POMALYST4 mg · Capsule | Pomalidomide | Canada | Marketed | 2014 |
Where it holds or makes medicines, with how many are current.
| Country | Medicines | Current | Past | Companies |
|---|---|---|---|---|
| Canada | 182 | 47 | 135 | CompaniesAll medicines |
The ATC groups most of its medicines belong to, largest first.
The active substances in most of its medicines.
How the registers spell it, normalised: legal forms, accents and capitals removed.
Compiled by Prognia from the public medicine and company registers below. Logos are not used.
Health Canada, Drug Product Database, company API, entire response observed 2026-10-10T15:12:05.508784+00:00; native facts projected by Prognia.
Licence: Open Government Licence Canada
Health Canada, Drug Product Database, drugproduct API, entire response observed 2026-10-10T15:12:07.336870+00:00; native facts projected by Prognia.
Licence: Open Government Licence Canada
Report an error or request removalCorrections from the company itself are welcome.
Other companies in the same group.
Ranked by their number of medicines.